On November 10, 2025, Cogent Biosciences announced positive results from its Phase 3 Trial of bezuclastinib for GIST, showing a 50% reduction in disease progression compared to sunitinib, with a median progression-free survival of 16.5 months versus 9.2 months for the latter. The company estimates a potential global market opportunity of over $4 billion for this treatment.